Gluskin Sheff & Assoc Inc Lineage Cell Therapeutics, Inc. Transaction History
Gluskin Sheff & Assoc Inc
- $797 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding LCTX
# of Institutions
135Shares Held
107MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$17.1 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$3.92 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$3.54 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$2.97 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$2.44 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $69.6M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...